Seres Therapeutics, Inc.MCRBNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank38
3Y CAGR-20.4%
5Y CAGR+24.1%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-20.4%/yr
vs +8.8%/yr prior
5Y CAGR
+24.1%/yr
Recent deceleration
Acceleration
-29.2pp
Decelerating
Percentile
P38
Within normal range
vs 5Y Ago
2.9x
Strong expansion
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $90.63M | -23.1% |
| 2024 | $117.78M | -39.6% |
| 2023 | $195.10M | +8.4% |
| 2022 | $179.91M | -14.1% |
| 2021 | $209.42M | +580.5% |
| 2020 | $30.77M | -71.1% |
| 2019 | $106.38M | -17.2% |
| 2018 | $128.55M | +4.1% |
| 2017 | $123.50M | +7.8% |
| 2016 | $114.61M | - |